RBRK

TentativeAI Memo

Rubrik

As of 2026-05-29/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-29 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators

Action

—

Confidence

medium

Horizon

—

Key catalyst

June 4 Q1 FY2027 print is the next proof point for FY2026 momentum • 2026-06-04

Expected move: +25%

Biggest risk

A meaningful share of growth still benefits from subscription-credit and material-rights timing, and management expects those benefits to taper sequentially through FY2027. That raises the risk of slower revenue growth even if ARR remains healthy. [#10-K-2026-03-19]

Invalidation

Break below $57 or thesis failure.

What would change my mind?

FY2026 ended with strong operating traction: Subscription ARR reached $1.46B, revenue reached $1.32B, free cash flow was positive and large, and customer count above $100K ARR continued to grow. Product expansion plus the MEDITECH healthcare collaboration can extend the land-and-expand cycle if execution holds.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-29

Base target

$103

p=55%

Bull target

$124

p=25%

Bear target

$57

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

MEDITECH collaboration opens a healthcare cross-sell lane
Product breadth continues to widen the platform story
FY2026 ended with strong operating traction: Subscription ARR reached $1.46B, revenue reached $1.32B, free cash flow was positive and large, and customer count above $100K ARR continued to grow.

BearKey bullets

FY2027 subscription revenue growth may slow as material-rights and subscription-credit benefits fade sequentially.
[#10-K-2026-03-19]
Healthcare and product wins may take time to convert into durable bookings, and the packet does not include any fresh analyst revision support to validate upside after the print.

WatchKey bullets

June 4 Q1 FY2027 print is the next proof point for FY2026 momentum

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $103 (p=55%)

Bull/Bear spread: +51% / -31%

Vs latest close: Bull +51% · Base +25% · Bear -31%

Scenario probabilities

Bull Target: $124 (p=25%)Base Target: $103 (p=55%)Bear Target: $57 (p=20%)

Commentary

Primary-source tone is constructive: Rubrik delivered a strong FY2026 print, issued FY2027 guidance, and added a healthcare collaboration that broadens the growth story. However, the packet does not include fresh analyst revisions, options data, or social context, and the post-print price reaction is not verified here, so conviction stays moderate rather than aggressive.

As of 2026-05-29 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

MEDITECH collaboration opens a healthcare cross-sell lane
Product breadth continues to widen the platform story

Scenarios

Bull Target (Scenario probability)

$124 / p=25% prob

Base Target (Scenario probability)

$103 / p=55% prob

Bear Target (Scenario probability)

$57 / p=20% prob

Price $82 as of 2026-06-02

Nearest Scenario: Base (∆ 25%)

Targets vs latest close: Bull +51% · Base +25% · Bear -31%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-06-04
June 4 Q1 FY2027 print is the next proof point for FY2026 momentum
Rubrik enters the June 4 earnings update after a March 12 FY2026 release that exceeded guided metrics, with Subscription ARR up 34% to $1.46B, Q4 revenue up 46% to $377.7M, and FY2026 free cash flow of $237.8M. The key question is whether that operating leverage can carry into FY2027. [#8-K-2026-03-12]
Prob 82.00% • Move 7.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

MEDITECH collaboration opens a healthcare cross-sell lane
2026-09-30
Rubrik and MEDITECH announced a strategic collaboration to provide native cyber resilience for MEDITECH self-hosted cloud and on-premises deployments, with immediate availability for select self-hosted cloud customers and early access for on-premises integrations. If adoption broadens, healthcare can become a durable vertical expansion vector.
Prob 58% • Move 4% • Priced-in 35%
Product breadth continues to widen the platform story
2026-12-31
The March 12 update highlighted Rubrik Agent Cloud, Rubrik Security Cloud Sovereign, Intelligent Business Recovery for Microsoft 365, and Rubrik DevOps Protection, which broaden the AI-governance, recovery, compliance, and developer-workflow stack. That breadth supports cross-sell and larger deal sizes if adoption stays healthy. [#8-K-2026-03-12]
Prob 65% • Move 5% • Priced-in 40%

Risks

FY2027 subscription revenue growth may slow as material-rights and subscription-credit benefits fade sequentially. [#10-K-2026-03-19]
Healthcare and product wins may take time to convert into durable bookings, and the packet does not include any fresh analyst revision support to validate upside after the print.
Quarterly revenue can still swing with renewals, customer exercises/forfeitures of Subscription Credits, and other timing effects. [#10-K-2026-03-19]
Sustaining operating leverage while funding AI features, product launches, and international expansion remains an execution risk. [#10-K-2026-03-19]

Peers

Symbol	Summary
CVLT	Most direct public operating peer in data protection and cyber resilience; useful for comparing Rubrik's subscription growth, recovery platform positioning, and path toward software margins. Rubrik's 10-K identifies Commvault among data management and protection competitors. [#10-K-2026-03-19]
IBM	Large incumbent data-management and infrastructure-security competitor named in Rubrik's 10-K; less valuation-clean because of IBM's broader mix, but relevant for enterprise account competition and incumbent displacement risk. [#10-K-2026-03-19]
CHKP	Mature cybersecurity peer with a stronger margin profile and slower growth; useful as a conservative security-software valuation anchor, though it is less directly tied to backup and recovery workloads.
CRWD	High-growth cybersecurity platform comparator for premium cyber multiples and enterprise security budgets; less direct than Commvault because endpoint and cloud security are not Rubrik's core data-protection market.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-29

AI Stock Memo: RBRK - Rubrik - RankAlpha